Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab

被引：12

作者：

Decaux, J. ^{[1
]}

Magremanne, M. ^{[1
,2
]}

机构：

[1] Dept Oral & Maxillofacial Surg, B-1200 Brussels, Belgium

[2] Catholic Univ Louvain, Clin Univ St Luc, Inst Roi Albert Cancerol & Hematol 2, Ave Hippocrate 10, B-1200 Brussels, Belgium

来源：

JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY | 2020年 / 121卷 / 06期

关键词：

Osteonecrosis; Jaw; Epacadostat; Pembrolizumab; Immunology; Immunotherapy; INHIBITORS; IDO1;

D O I：

10.1016/j.jormas.2020.05.001

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

MRONJ is a well-known side effect of various medications, such as antiresorptive drugs, anti-angiogenic agents, immunomodulators and immunosuppressants. MRONJ related to immunotherapy is rarely described, with only one case related to ipilimumab. The interaction between the immune system and osteoclast lineage cells is well known. T cells release factors and cytokines that control osteoclastogenesis, and osteoclasts produce factors with an action on T cells. We attempted to explain how immunotherapy could cause MRONJ through the case report of a young patient with metastatic melanoma who developed maxilla MRONJ after pembrolizumab and epacadostat treatment. (c) 2020 Elsevier Masson SAS. All rights reserved.

引用

页码：740 / 742

页数：3

共 12 条

[1] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, Celine
Tarhini, Ahmad
Routier, Emilie
Lambotte, Olivier
Ladurie, Francois Leroy
Carbonnel, Franck
Izzeddine, Hassane
Marabelle, Aurelien
Champiat, Stephane
Berdelou, Armandine
Lanoy, Emilie
Texier, Matthieu
Libenciuc, Cristina
Eggermont, Alexander M. M.
Soria, Jean-Charles
Mateus, Christine
Robert, Caroline
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 473 - 486
[2] T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway
Bozec, Aline
Zaiss, Mario M.
Kagwiria, Rosebeth
Voll, Reinhard
Rauh, Manfred
Chen, Zhu
Mueller-Schmucker, Sandra
Kroczek, Richard A.
Heinzerling, Lucie
Moser, Muriel
Mellor, Andrew L.
David, Jean-Pierre
Schett, Georg
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (235)
[3] Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw
Chang, J.
Hakam, A. E.
McCauley, L. K.
[J]. CURRENT OSTEOPOROSIS REPORTS, 2018, 16 (05): : 584 - 595
[4] Cutaneous adverse effects of the immune checkpoint inhibitors
Collins, Lindsey K.
Chapman, M. Shane
Carter, Joi B.
Samie, Faramarz H.
[J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 125 - 128
[5] Inhibitory Signals Mediated by Programmed Death-1 Are Involved With T-Cell Function in Chronic Periodontitis
Figueira, Eduardo Aleixo
Rubo de Rezende, Maria Lucia
Torres, Sergio Aparecido
Garlet, Gustavo Pompermaier
Lara, Vanessa Soares
Santos, Carlos Ferreira
Avila-Campos, Mario Julio
da Silva, Joao Santana
Campanelli, Ana Paula
[J]. JOURNAL OF PERIODONTOLOGY, 2009, 80 (11) : 1833 - 1844
[6] Oral health in oncology: impact of immunotherapy
Jackson, Leanne K.
Johnson, Douglas B.
Sosman, Jeffrey A.
Murphy, Barbara A.
Epstein, Joel B.
[J]. SUPPORTIVE CARE IN CANCER, 2015, 23 (01) : 1 - 3
[7] Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Komiya, Takefumi
Huang, Chao H.
[J]. FRONTIERS IN ONCOLOGY, 2018, 8
[8] The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Mbongue, Jacques C.
Nicholas, Dequina A.
Torrez, Timothy W.
Kim, Nan-Sun
Firek, Anthony F.
Langridge, William H. R.
[J]. VACCINES, 2015, 3 (03) : 703 - 729
[9] Osteonecrosis of the jaw a new complication related to Ipilimumab
Owosho, Adepitan A.
Scordo, Michael
Yom, SaeHee K.
Randazzo, Joseph
Chapman, Paul B.
Huryn, Joseph M.
Estilo, Cherry L.
[J]. ORAL ONCOLOGY, 2015, 51 (12) : E100 - E101
[10] Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System
Ponzetti, Marco
Rucci, Nadia
[J]. FRONTIERS IN ENDOCRINOLOGY, 2019, 10

← 1 2 →